Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (12342)	12/9/1997 6:50:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

mz, I have to do some more research, but how specific are the phosphatase inhibitors? As you know most polypeptide hormones (growth factors, interleukins, and interferons) start by binding to a TK receptor leading to tyrosine phosphorylation which in turn can be regulated by phosphatases. I have always wondered about the relative merits of an approach that targetted the front end of the signalling pathway (Tyrosine phospoorylation and dephosphorylation), verses the back end (transcription factors and associated regulatory proteins). LGND of course is targeting the backend and with diabetes and others diseases they will be moving toward combinations to increase specificity (for insulin resistance its ligands for RXRalpha combined with ligands for PPARgamma). Of course with the back end targets, LGND has on (agonists) and off (antagonists) compounds and eventually will be able to do quite a bit of mixing and matching.